Wednesday, 26 August 2026European Markets

SOC FRANC CASINOS Stock Bullish Momentum With A 10.61% Jump On Monday

Loading stream...

(vianews) - the market ended the session with soc franc casinos (sfca.pa) rising 10.61% to €1.98 on monday, following the last session's upward trend. cac 40 dropped 0.28% to €7,498.18, after five successive sessions in a row of gains, on what was a somewhat negative trend trading session today.

soc franc casinos's last close was €1.79, 11.39% under its 52-week high of €2.02.

about soc franc casinos

société française de casinos société anonyme operates casinos in france. the company is also involved in the hotel and restaurant activities. the company is based in paris, france.

earnings per share

as for profitability, soc franc casinos has a trailing twelve months eps of €0.34.

pe ratio

soc franc casinos has a trailing twelve months price to earnings ratio of 5.82. meaning, the purchaser of the share is investing €5.82 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 18.61%.

yearly top and bottom value

soc franc casinos's stock is valued at €1.98 at 22:33 est, under its 52-week high of €2.02 and way higher than its 52-week low of €1.36.

more news about soc franc casinos (sfca.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Query this data → isubstrate.com